Reviewing Positron (POSC) & Its Peers

Positron (OTCMKTS:POSC) is one of 70 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its competitors? We will compare Positron to related companies based on the strength of its analyst recommendations, dividends, profitability, institutional ownership, valuation, risk and earnings.

Profitability

This table compares Positron and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Positron	-300.00%	N/A	-89.57%
Positron Competitors	-350.61%	-97.06%	-31.48%

Insider and Institutional Ownership

44.2% of shares of all “Electromedical equipment” companies are owned by institutional investors. 17.2% of Positron shares are owned by insiders. Comparatively, 13.6% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Positron has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Positron’s competitors have a beta of 18.19, indicating that their average share price is 1,719% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Positron and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Positron	0	0	0	0	N/A
Positron Competitors	257	779	1923	59	2.59

As a group, “Electromedical equipment” companies have a potential upside of 3,135.23%. Given Positron’s competitors higher possible upside, analysts plainly believe Positron has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Positron and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Positron	$740,000.00	-$1.64 million	-11.75
Positron Competitors	$1.06 billion	$91.09 million	-8.12

Positron’s competitors have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Positron competitors beat Positron on 7 of the 10 factors compared.

About Positron

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.